Participants with no exacerbations in study period · chronic bronchitis or COPD
Mucolytic probably leads to higher participants with no exacerbations in study period compared with placebo (moderate certainty).
1 finding from 1 review
Days of disability per participant per month · chronic bronchitis or COPD
1 finding from 1 review
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · chronic bronchitis or COPD
1 finding from 1 review
Hospitalisation during study period · chronic bronchitis or COPD
Mucolytic probably leads to lower hospitalisation during study period compared with placebo (moderate certainty).
1 finding from 1 review
FEV₁at end of study · chronic bronchitis or COPD
1 finding from 1 review
Adverse effects · chronic bronchitis or COPD
Mucolytic probably leads to lower adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
Death during study period · chronic bronchitis or COPD
Mucolytic showed no clear difference in death during study period compared with placebo (moderate certainty).
1 finding from 1 review
Mortality. · adult parapneumonic effusions and empyema
Fibrinolytics showed no clear difference in mortality. compared with placebo (moderate certainty).
1 finding from 1 review
Referral for thoracic surgery (open or thorascopic) · adult parapneumonic effusions and empyema
Fibrinolytics may leads to lower referral for thoracic surgery. compared with placebo (low certainty).
1 finding from 1 review
Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy · adult parapneumonic effusions and empyema
It is very uncertain whether fibrinolytics changes overall treatment failure, including mortality, thoracic surgery or… compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events · adult parapneumonic effusions and empyema
Fibrinolytics showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Respiratory exacerbations: number of respiratory exacerbations per year · Adults with COPD
1 finding from 1 review
Exacerbations needing hospitalisation · Adults with COPD
1 finding from 1 review
All‐cause mortality · Adults with COPD
Statins showed no clear difference in all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
COPD‐specific mortality · Adults with COPD
Statins showed no clear difference in COPD‐specific mortality compared with placebo (low certainty).
1 finding from 1 review
Quality of life · Adults with COPD
Statins led to lower quality of life compared with placebo; GRADE not reported.
1 finding from 1 review
Adverse events · Adults with COPD
1 finding from 1 review
All‐cause mortality (3‐week to 1‐year · Adults with COPD
Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in all‐cause mortality (3‐week to 1‐year compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events (3‐week to 1‐year · Adults with COPD
Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in serious adverse events (3‐week to 1‐year compared with placebo (high certainty).
1 finding from 1 review
COPD exacerbations · Adults with COPD
Once‐daily LABA/LAMA in a combined inhaler probably leads to lower acute exacerbations of COPD (4‐week to 24‐week compared with placebo (moderate certainty).
1 finding from 1 review